d.ee_angelo / Shutterstock.com
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.
The US Inflation Reduction Act (IRA) came into force on August 16 2022.
Over the past 12 months, most life sciences manufacturers with products expected to be reimbursed by the US Medicare system have now internalised, at least to some extent, the impact that the act will have on their research and development and commercial launch strategies.
What the industry may not yet have grasped is the impact it is likely to have on their IP partnering, collaboration, and patent litigation strategies. The new IRA framework raises a number of considerations for IP practitioners supporting life sciences companies of any size.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Hogan Lovells, US inflation reduction act, Medicare, QSSD, IP practitioners, QSSD, NDA, Biologics License Application